Harrow (HROW) Posts Record Q3 Revenue As New Acquisition Sets Up Q4 Catalyst

• Harrow (NasdaqGM:HROW) reported record Q3 2026 revenue, supported by higher branded ophthalmic product sales.
• The company closed its acquisition of dry eye therapy TYRVAYA in Q3 2026, expanding its branded product portfolio.
• Management updated full year 2026 revenue and EBITDA guidance, citing contributions from branded products and integration spending.
• Record Q3 revenue and the TYRVAYA deal only tell part of Harrow's story for the coming quarters. We have also flagged 3 other big wins for Harrow.

Harrow is far from the only ophthalmic or eye care focused player tied to this trend of branded therapies, so it is worth scanning peers exposed to similar treatment and data driven healthcare themes through 36 healthcare AI stocks.

Harrow focuses on prescription treatments for eye conditions in the US market, so record revenue and the TYRVAYA acquisition plug directly into its core ophthalmic portfolio rather than a side business.

Harrow’s TYRVAYA deal shifts the Narrative from single-product bets to a fuller dry eye and access platform story

The investment story on Harrow hinges on whether a broader ophthalmic portfolio and the HarrowRx access model can turn more prescriptions into sustained, higher quality revenue. Record Q3 figures and the closing of TYRVAYA plug straight into that Narrative because they test whether breadth and execution really travel together.

"The main requirement is consistent execution on pricing, gross-to-net management, and integration of new products such as TYRVAYA so that revenue contribution from recent launches and acquisitions offsets current profitability pressure and elevated SG&A…"

See how the full story points towards a $63.00 fair value for Harrow.

This update leans toward the bull case that Harrow is shifting from a few flagship products to a multi-franchise model. TYRVAYA brings another dry eye stream into the mix, while Q3 2026 revenue of US$99.3 million and positive quarterly net income show the enlarged commercial engine can support more branded lines without Harrow looking like a one-drug story against players such as Alcon or AbbVie.

The bear side is not cleared away. Nine month figures still show a net loss of US$35.12 million, which means integration spending, higher SG&A and the added TYRVAYA field force all need to earn their keep quickly through HarrowRx enabled prescription capture and cleaner gross to net outcomes, not just headline portfolio breadth.

News like this only becomes useful for you as an investor when it is weighed against a clear Narrative about how Harrow plans to turn a bigger portfolio and access platform into durable economics over time.

Add Harrow to your Watchlist and get alerts as these catalysts play out.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com